The DOI matches its Crossref record.
A randomized comparison of intra-arterial versus intravenous with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma
Abstract
✓ This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every weeks), each regimen without or with intravenous 5-fluorouracil gm/sq m three times daily given 2 weeks after BCNU). All patients also received radiation therapy. A total of 505 patients were randomly assigned within the study. Fifty-seven patients were excluded, primarily because of neuropathology error, and the remaining 448 patients constituted the Valid Study Group. Of the total 505 patients, 190 patients could not receive intra-arterial BCNU and 315 patients were randomly assigned to receive intra-arterial (167 patients) and intravenous (148 patients) BCNU. Actuarial analysis (log-rank) demonstrated reduced survival for the intra-arterial group (p = 0.03). Serious toxicity was observed in the intra-arterial group; 16 patients (9.5%) developed irreversible encephalopathy with computerized tomography evidence of cerebral edema, and 26 patients (15.5%) developed visual loss ipsilateral to the infused carotid artery. Administration of 5-fluorouracil did not influence survival. The survival rate between the intravenous and the intra-arterial BCNU patients with glioblastoma multiforme did not differ, but was worse for intra-arterial BCNU patients with anaplastic astrocytoma than for those receiving intravenous BCNU (p = 0.002). Neuropathologically, intra-arterial BCNU produced white matter necrosis. It is concluded that intra-arterial BCNU is neither safe nor effective in prolonging survival when administered by the methods used in this study of newly diagnosed patients with malignant glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment
Giese, A., Bjerkvig, R., Berens, M. E., & Westphal, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.063 · Cited by 1,200
Cognitive deficits in adult patients with brain tumours
Taphoorn, M. J., & Klein, M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00680-5 · Cited by 756
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Guillaume, D. J., Doolittle, N. D., Gahramanov, S., Hedrick, N. A., Delashaw, J. B., & Neuwelt, E. A. (2010) · PubMed · doi:10.1227/01.neu.0000363152.37594.f7 · Cited by 420
Doolittle, N. D., Miner, M. E., Hall, W. A., Siegal, T., Hanson, E. J., Osztie, E., McAllister, L. D., Bubalo, J. S., Kraemer, D. F., Fortin, D., et al. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000201)88:3<637::aid-cncr22>3.0.co;2-y · Cited by 399
Liu, H.-L., Hua, M.-Y., Chen, P.-Y., Chu, P.-C., Pan, C.-H., Yang, H.-W., Huang, C.-Y., Wang, J.-J., Yen, T.-C., & Wei, K.-C. (2010) · Radiology · doi:10.1148/radiol.10090699 · Cited by 393
Intra-arterial Chemotherapy for Retinoblastoma: A Systematic Review
Yousef, Y. A., Soliman, S. E., Astudillo, P. P. P., Durairaj, P., Dimaras, H., Chan, H. S. L., Héon, E., Gallie, B. L., & Shaikh, F. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.0244 · Cited by 370
Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1271 · Cited by 341
The molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Liu, H.-L., Fan, C.-H., Ting, C.-Y., & Yeh, C.-K. (2014) · Theranostics · doi:10.7150/thno.8074 · Cited by 276
Klatzmann, D., Valery, C. A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.-L., Philippon, J., & Glioblastoma, S. G. O. G. T. F. (1998) · Human Gene Therapy · doi:10.1089/10430349850019436 · Cited by 269
Selker, R. G., Shapiro, W. R., Burger, P., Blackwood, M. S., Deutsch, M., Arena, V. C., Van Gilder, J. C., Wu, J., Malkin, M. G., Mealey, J., et al. (2002) · Neurosurgery · doi:10.1097/00006123-200208000-00009 · Cited by 260
Self-citationAdvances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy
Rapoport, S. I. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.10.1809 · Cited by 147
McCarty, D. M., DiRosario, J., Gulaid, K., Muenzer, J., & Fu, H. (2009) · Gene Therapy · doi:10.1038/gt.2009.85 · Cited by 105
Metadata
- Authors
- Shapiro, W. R., Green, S. B., Burger, P. C., Selker, R. G., VanGilder, J. C., Robertson, J. T., Mealey, J., Ransohoff, J., & Mahaley, M. S.
- Venue
- Journal of Neurosurgery
- Published
- 1992-05
- Volume
- 76
- Issue
- 5
- Pages
- 772-781
- ISSN
- 0022-3085 (ISSN-L)
- OpenAlex
- W2170160933
- Cited by
- 243
- References
- 0
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.